Independent brokers in the region need to know whether it is going to them
Mark Rosanes Aug 27, 2026
As weight-loss become more accessible, the controls behind prescribing could become as important to insurers as the medicines themselves
Data migration to SS&C is still underway, a second deal closes before it completes, and 440,000 former HSBC Life UK protection policyholders are in a system that is actively changing
This summer's excess deaths are financially real for European life re/insurers. S&P's conclusion is that the market can absorb them. Its warning is about what happens as temperatures keep rising and populations keep ageing
An oral GLP-1 that can be taken at any time without food restrictions is cheaper, harder to verify, and easier to fake than its injectable predecessors. Life and health brokers need to get ahead of what that means for their clients
The platform's future under new ownership, client continuity, and transition terms: these are the questions advisers should be raising with their account contacts now, not after completion
Zurich's ClearView completion signals a broader push into protection as composite insurers rebuild what rivals spent years dismantling
A five-point move in the market's largest retail product signals a pricing squeeze that will reach brokers' clients at renewal
Britain becomes the first country in Europe to licence Mounjauro/Ozempic competitor
AXA's Matt Briggs discusses the emerging risks reshaping commercial property insurance, from lithium-ion batteries and net zero retrofits to climate change and what underwriters look for in a well-managed risk
Prevention, collaboration and changing expectations are reshaping construction insurance. AXA's Andrew Hogg shares where the market is heading
Coverdrone's Phil Heath and Richard Webb discuss the growth of drone insurance and what it reveals about insuring emerging technologies.
